Target intelligence / Profile preview

RWDD3 divergent transcript (RWDD3-DT)

Target
RWDD3-DT
Molecular classification
Other (lncRNA, long non-coding RNA)
01

Overview

RWDD3 divergent transcript (RWDD3-DT) is a long non-coding RNA (lncRNA) gene located on human chromosome 1 (chr1:95161676-95234108, hg38)[4][5]. It does not encode a protein but belongs to the class of divergent transcripts associated with, but distinct from, the protein-coding RWDD3 gene[5]. There is no evidence that RWDD3-DT acts as a therapeutic target such as a receptor, enzyme, transporter, or related pharmacological category[4][5]. Current genomic databases (GeneCards, BioGPS, Ensembl) classify RWDD3-DT strictly as a non-coding RNA and not as a traditional druggable target. No common drugs, biomarkers, or mechanisms of action are reported. There are no known safety concerns associated uniquely with the transcript due to its non-coding nature. The functional significance of RWDD3-DT, if any, lies in potential regulatory roles common to lncRNAs, but no widely accepted biological or disease function is described in current sources[4][5]. **Note:** RWDD3-DT should not be confused with the protein-coding gene RWDD3, which has distinct functions and disease associations[2][3][6].

Other names
RWDD3 divergent transcriptRWDD3-DT
02

Biological functions

Other (no direct protein-coding or enzymatic/receptor function; implicated in regulation of expression and possibly chromatin-level gene regulation)
03

Disease associations

Other (potential involvement in cancer, specifically non-small cell lung cancer based on lncRNA-related literature, but no direct evidence of causative or broad disease roles found)

Beyond the preview

Go deeper on RWDD3 divergent transcript (RWDD3-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RWDD3 divergent transcript (RWDD3-DT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call